Agile Therapeutics, Inc. (NASDAQ:AGRX) reached -64.25% versus a 1-year low price of $1.93. The stock was last seen -72.4% lower, reaching at $0.69 on 05/18/2018. At recent session, the prices were hovering between $0.58 and $1.02. This company shares are 943.48% off its target price of $7.2 and the current market capitalization stands at $85.6M. The recent change has given its price a -75.99% deficit over SMA 50 and -87.68% deficit over its 52-week high. The stock witnessed -76.21% declines, -81.3% declines and -84.49% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AGRX’s volatility during a week at 20.84% and during a month it has been found around 9.64%.Agile Therapeutics, Inc. (AGRX) Top Holders
Institutional investors currently hold around $17 million or 80.5% in AGRX stock. Look at its top three institutional owners. Proquest Associates Iv Llc owns $3.49 million in Agile Therapeutics, Inc., which represents roughly 4.08% of the company’s market cap and approximately 20.55% of the institutional ownership. Similar statistics are true for the second largest owner, Perceptive Advisors Llc, which owns 3,530,000 shares of the stock are valued at $2.44 million. The third largest holder is Investor Ab, which currently holds $2.42 million worth of this stock and that ownership represents nearly 2.83% of its market capitalization.
At the end of 03/31/2018 reporting period, 19 institutional holders increased their position in Agile Therapeutics, Inc. (NASDAQ:AGRX) by some 1,663,559 shares, 24 decreased positions by 1,303,660 and 11 held positions by 21,714,836. That puts total institutional holdings at 24,682,055 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 689,419 shares while 8 institutional investors sold out their entire positions totaling 489,636 shares.Agile Therapeutics, Inc. (NASDAQ:AGRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Agile Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chairman & Chief Executive Off Altomari Alfred has acquired 10,000 shares of Agile Therapeutics, Inc. (AGRX) in trading session dated Aug. 25, 2017. These shares are worth $33,400 and were traded at $3.34 each. The SEC filing shows that Selman Renee performed a purchase of 7,250 shares. The Chief Commercial Officer added these shares by way of transaction on Aug. 25, 2017. The company’s shares were assimilated at $3.35 per share worth to an investment of some $24,288 on account of Selman Renee.
Chairman and Chief Executive O, Altomari Alfred, purchased 10,000 common shares of Agile Therapeutics, Inc. (AGRX) in the open market. In a transaction dated May. 11, 2017, the shares were bought at an average price of $3.51, giving away a sum of $35,100. After this purchase, 151,587 common shares of AGRX are directly owned by the insider, with total stake valued at $104,595.
In the transaction dated May. 11, 2017, the great number of shares acquired came courtesy the Chief Commercial Officer; Selman Renee added a total of 53,333 shares at an average price of $3.68, amounting to approximately $196,265. The insider now directly owns 53,333 shares worth $36,800.Agile Therapeutics, Inc. (AGRX) Analyst Guide
Several analysts have released their opinion on Agile Therapeutics, Inc. (NASDAQ:AGRX), with 3 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation.